HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Skinvisible Pharmaceuticals

This article was originally published in The Rose Sheet

Executive Summary

Las Vegas-based firm says its hand sanitizer lotion DermSafe kills/inactivates the H1N1 virus to the same detection level as 70% alcohol, as demonstrated in clinical testing carried out by Bioscience Laboratories, using American Society for Testing and Materials standards. Skinvisible says the outcome confirms results from previously announced in-vitro study conducted at European contract research organization Retroscreen Virology, which found the product achieves a 99.9% kill/inactivation of the H1N1 virus. "In some countries, this [research] allows Skinvisible to submit data for approval to include 'Kills H1N1' on the product label," firm notes. President and CEO Terry Howlett says latest clinical study "proves that Dermsafe is an effective alternative to alcohol, without the drying and safety issues." Active ingredient in DermSafe is chlorhexidine gluconate 4%, "used in hospital surgery rooms worldwide for over 50 years as a pre-surgical hand scrub," and contains the firm's Invisicare polymer delivery system that binds to skin, resisting wash-off for up to four hours for "continuous antimicrobial protection," according to Skinvisible. FDA and the Federal Trade Commission have joined forces in the U.S. to crack down on H1N1 claims by supplement manufacturers (1"The Tan Sheet" Oct. 19, 2009)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS016568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel